Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System
Open Access
- 18 March 2020
- journal article
- letter
- Published by S. Karger AG in Acta Haematologica
- Vol. 143 (6), 600-602
- https://doi.org/10.1159/000505605
Abstract
Treating patients with diffuse large B-cell lymphoma (DLBCL) remains a challenge, with a remission rate of 75% at 2 years from diagnosis. The International Prognostic Index (IPI) [1] and molecular characterization [2] are employed in the stratification and relapse prediction. Additionally, 18F-fluorodeoxyglucose positron emission tomography (PET) and computed tomography (CT) have now become part of standard care in differentiating metabolic activity of the disease from fibrosis or necrosis [3]. Early optimism that the speed of response to treatment, as indicated by an interim-PET (iPET) scan after 2–3 cycles of chemotherapy, might reliably predict cure has not been fulfilled [4].Keywords
This publication has 9 references indexed in Scilit:
- Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with T Cell Lymphomas Participating in the PETAL TrialBlood, 2016
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBlood, 2016
- Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor scoreOncotarget, 2016
- The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regionsLeukemia & Lymphoma, 2016
- Speed bumps on the road to a chemotherapy-free world for lymphoma patientsBlood, 2016
- Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell LymphomaJournal of Nuclear Medicine, 2014
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraBlood, 2014
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironmentBlood, 2011
- Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six GenesThe New England Journal of Medicine, 2004